Ready to start your Wolverine protocol
In a retrospective cohort study including 7,044 patients with T2D, obesity (BMI 27 kg/m 2 ) and HFpEF, combination therapy with an SGLT2i and GLP-1 RA showed a lower risk of HF exacerbation, all-cause emergency department visits and new-onset kidney injury compared with patients only receiving SGLT2i
Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review
From 2 months postpartum to 12 months postpartum, carnitine and acetylcarnitine milk concentrations were lower, in the range of 6.1 to 8.9 mg/L for carnitine and 1.2 to 2 mg/L for acetylcarnitine.[6] Ten mothers of full-term infants and mothers of preterm infants (36 weeks gestation or less) provided blood and milk samples for measurement of carnitine at 4 times during the first month postpartum
Data from observational studies and subgroup analyses of RCTs show that GLP-1 RAs reduce HF outcomes and mortality in obese HF patients across the LVEF spectrum
Yet almost no one acknowledges a critical fact: The clinical trials demonstrating DSIPs sleep effects used intravenous administration , and NOT the subcutaneous injections people are doing at home